Xarelto Dangerous Drug Litigation
Xarelto (rivaroxaban) is one of a new class of anticoagulants (blood thinners) called direct factor Xa inhibitors manufactured by Janssen Pharmaceuticals (a Johnson & Johnson pharmaceutical company), and Bayer. Xarelto is prescribed for three primary indications:
• to reduce the risk of blood clots and stroke in patients with atrial fibrillation
• to treat deep vein thrombosis and pulmonary embolism
• to reduce the risk of blood clots in patients undergoing knee or hip replacement surgery
Xarelto has been linked to a large number of injuries requiring hospitalization, with some resulting in death. Like all blood thinners, Xarelto can cause serious internal bleeding in some. Xarelto bleeding is difficult to stop, as there is currently no known reversal agent for this occurrence, therefore hemorrhaging will continue until the drug is cleared from the system. Additionally, stopping the use of Xarelto puts patients at high risk for stroke or systemic embolism and other thrombotic events, including myocardial infarction (MI) and death up to 30 days post-discontinuation.
Wexler Wallace LLP represents individuals who have been injured while taking Xarelto. If you or someone you know has experienced any of the symptoms listed above as a result of taking Xarelto, you may be eligible to file a suit. Please contact us or complete our online form.